New Study Shows Pfizer COVID-19 Pill Provides “No Significant Benefit” For Individuals Under Age 65

Pfizer COVID-19 Pill Does Not Provide Significant Benefit
Israeli scientists analyzed data provided by a major healthcare provider in the country, Clalit Health Services, covering 109,213 individuals who had eligibility to receive Pfizer’s Nirmatrelvir pill, also known by the name Paxlovid, between January 9 and March 10. File photo: Cryptographer, Shutter Stock, licensed.

NEW YORK, NY – A new COVID-19 pill developed by Pfizer that is intended to cut down on serious cases of the virus has been proven effective for elderly persons, those over 65, while ineffective for individuals under the age of 65, according to a recently-released study.

Israeli scientists analyzed data provided by a major healthcare provider in the country, Clalit Health Services, covering 109,213 individuals who had eligibility to receive Pfizer’s Nirmatrelvir pill, also known by the name Paxlovid, between January 9 and March 10.

Of those who were eligible, only 3 percent – approximately 2,500 – took the pill; among those who did not take it, 762 people were hospitalized and 151 died, whereas among those who took the pill, only 14 were hospitalized and 2 died.


FREE DIGITAL SUBSCRIPTION: GET ONLY 'FEATURED' STORIES BY EMAIL

Big Tech is using a content filtering system for online censorship. Watch our short video about NewsGuard to learn how they control the narrative for the Lamestream Media and help keep you in the dark. NewsGuard works with Big-Tech to make it harder for you to find certain content they feel is 'missing context' or stories their editors deem "not in your best interest" - regardless of whether they are true and/or factually accurate. They also work with payment processors and ad-networks to cut off revenue streams to publications they rate poorly by their same bias standards. This should be criminal in America. You can bypass this third-world nonsense by signing up for featured stories by email and get the good stuff delivered right to your inbox.
 

However, among the younger participants in the study, those numbers changed dramatically, according to the researchers conducting the program.

“The findings from our current study suggest that during the omicron variant surge, COVID-19 hospitalizations rates were significantly lower in adults aged 65 years and above in nirmatrelvir treated participants, both in patients with and without prior Covid-19 immunity,” they said. “However, no significant benefit was shown in the younger cohort.”

The death rate of people under the age of 65 who took Paxlovid was 0.07 percent, versus 0.2 percent among those who did not receive the pill; 0.6 percent of those who received Paxlovid were hospitalized, as opposed to 0.5 percent who didn’t take the drug.

The Israeli study – which is based on real-world data when the Omicron virus variant was dominant – has yet to be peer-reviewed. However, health officials in the United States currently recommend Paxlovid as a treatment option for adults who may be at high-risk for developing “severe” cases of COVID-19.


Comment via Facebook

Corrections: If you are aware of an inaccuracy or would like to report a correction, we would like to know about it. Please consider sending an email to corrections@publishedreporter.com and cite any sources if available. Thank you. (Policy)